
Commentary|Podcasts|July 15, 2025
COBRRA Trial Results Raise Questions About VTE Management
The COBBRA trial compared bleeding risk with rivaroxaban vs apixaban in patients with acute venous thromboembolism.
Advertisement
This week, host Craig Beavers sat down with Tara Lech, PharmD, CACP, director of anticoagulation services at Beth Israel Lahey Health, to discuss recent findings from the COBBRA trial, which compared bleeding risk with rivaroxaban vs apixaban in patients with acute venous thromboembolism.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Updated Hypertension Guidelines Are Here
2
Striking the Balance: Evidence-Based versus Defensive Medicine
3
Carefully Consider Ethical Implications of Artificial Intelligence Use in Pharmacy
4
Learning From Last Season: What RSV Rates Tell Us About Vaccination Needs This Year
5


















































































































































































































